Stay updated on Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.

Latest updates to the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe ClinicalTrials.gov record for the lirentelimab study is now displayed rather than an error page. It provides the study’s details, including that it is terminated and no longer recruiting, along with eligibility, locations, design, outcomes, and study documents.SummaryDifference78%

- Check15 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces an NIH transition update, including that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” under Executive Order 14434.SummaryDifference1%

- Check29 days agoChange DetectedThe footer revision label changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now includes the study documents (SAP, Study Protocol) and IPD sharing plan, along with related metadata updates, which contextualize the trial's methodology and governance.SummaryDifference80%

Stay in the know with updates to Subcutaneous Lirentelimab in Urticaria: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.